Sarah Cannon Research Institute at HealthONE Grand Opening

The HealthONE Family of Hospitals and Sarah Cannon announced today that the grand opening of Sarah Cannon Research Institute at HealthONE, a phase 1 cancer clinical trials program in Denver, Colo., will take place on February 25. Sarah Cannon Research Institute at HealthONE offers cancer patients in the Rocky Mountain region access to the newest targeted cancer therapies, and its reach far extends past Colorado. "Qualifying patients throughout the country can also participate in clinical trials making it a destination for key cancer services," said Sylvia Young, President and CEO, HealthONE, the largest healthcare system in the metro Denver area with more than 10,000 employees.

The facility offers not only a clinic but also investigational pharmacy, lab space, and an infusion center. The program is led by Gerald Falchook, MD, MS who brings with him extensive experience cancer research, having served as an investigator on more than 160 clinical studies. Dr. Falchook completed his oncology training at MD Anderson Cancer Center, where he also served as a faculty member for six years, developing investigator-initiated clinical trials, as well as collaborating with pharma/biotech industry partners to bring promising new drugs to cancer patients.

"Through Sarah Cannon Research Institute at HealthONE, we are not only able to give patients access to the most novel therapies available for investigation, but we also have a supportive team of nurses, pharmacists, and lab personnel," said Dr. Falchook. "In addition, our alignment with Sarah Cannon connects us to a global network of more than 1,000 oncologists across the world engaged in clinical research."

Sarah Cannon Research Institute has more than 20 years of experience conducting community-based clinical trials, including more than 150 first-in-human studies to date, and a role in clinical trials that led to the approval of approximately 80 percent of approved cancer therapies over the last three years.

"The opening of this program enables us to combine our clinical trial experience with Sarah Cannon Research Institute's world-renowned cancer research, allowing us to deliver the most advanced and personalized care," said Young. "This is an important step in our initiative to bring additional early-phase investigational treatments to patients in Denver and our region."

Want to learn more about Sarah Cannon Research Institute at HealthONE? Visit our comprehensive website, including a list of our clinical trials, here.